Illustrative“Still a Ways to Go”: Takeaways From ASCO 2026 in EGFR-Mutated NSCLC
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
A recent event, ASCO 2026, has taken place, focusing on EGFR-mutated non-small cell lung cancer. The event has yielded takeaways, suggesting that there is still progress to be made in this area. The implications of these takeaways are being considered.